Treatment outcomes among patients with drug-resistant tuberculosis managed with BPaL/BPaLM regimen in the Southeast Zone of Nigeria
Abstract
Introduction the treatment of multidrug-resistant tuberculosis (MDR-TB) has been challenging, often associated with life-threatening adverse events and poor treatment outcomes. The recent World Health Organization (WHO) recommendation of the BPaLM regimen, consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin for treatment of pre-extensively drug-resistant tuberculosis (Pre-XDR) and rifampicin-resistant tuberculosis (MDR-TB/RR), has been shown to have favorable treatment outcomes. This study focused on the outcomes of patients managed with this regimen in the southeastern zone of Nigeria between November 2023 and October 2024, following approval by the National Tuberculosis and Leprosy Control Program (NTBLCP) in November 2023. Methods patient demographic and clinical data were collected from DR-TB treatment registers, active drug safety monitoring forms (aDSM), and laboratory registers using an abstraction tool. Data were analyzed using descriptive statistics such as frequency and percentages for variables such as age, gender, adverse events, new and retreatment cases, treatment outcomes such as completed treatment, cured, loss to follow-up (LTFU), and death. Results out of the 212 patients enrolled for treatment during the period, 202 patients were treated for MDR-TB/RR with BPaLM, while 10 were treated for Pre-XDR with BPaL. The TSR for the MDR-TB/RR category is 89%, while the TSR for the Pre-XDR category is 100%. More than 6.7% of the patients in the…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.